New hope for Hard-to-Treat myeloma: first human trial of ABBV-438 begins
NCT ID NCT07409246
First seen Feb 20, 2026 · Last updated May 22, 2026 · Updated 15 times
Summary
This early-stage study tests a new drug called ABBV-438 in about 127 adults with multiple myeloma that has returned or not responded to prior treatments. The main goals are to check the drug's safety, find the best dose, and see if it helps shrink the cancer. Participants receive the drug through an IV, and the study lasts about 5.8 years total.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
City Of Hope - Atlanta. /ID# 280294
RECRUITINGNewnan, Georgia, 30265, United States
-
City of Hope - Orange County Lennar Foundation Cancer Center /ID# 279067
RECRUITINGIrvine, California, 92618, United States
-
City of Hope National Medical Center /ID# 280273
RECRUITINGDuarte, California, 91010, United States
-
Colorado Blood Cancer Institute /ID# 280275
RECRUITINGDenver, Colorado, 80218, United States
-
Hadassah Medical Center-Hebrew University /ID# 278865
RECRUITINGJerusalem, 91120, Israel
-
START Midwest /ID# 279035
RECRUITINGGrand Rapids, Michigan, 49546, United States
-
Tel Aviv Sourasky Medical Center /ID# 279066
RECRUITINGTel Aviv, Tel Aviv, 6423906, Israel
-
The Cancer Institute Hospital Of JFCR /ID# 279069
RECRUITINGKoto-ku, Tokyo, 135-8550, Japan
-
The Chaim Sheba Medical Center /ID# 279065
RECRUITINGRamat Gan, Tel Aviv, 5265601, Israel
Conditions
Explore the condition pages connected to this study.